Ernexa Therapeutics Inc. Capital Leases, Income Statement, Sales Type Lease Revenue
Ernexa Therapeutics Inc. (ERNA) reported Capital Leases, Income Statement, Sales Type Lease Revenue of $679.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Income Statement › Other Income
us-gaap:CapitalLeasesIncomeStatementSalesTypeLeaseRevenue · last filed 2018-05-11
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for the quarter ending 2018-03-31 was $679.00K, a 267.03% increase year-over-year.
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for the quarter ending 2017-12-31 was $246.00K, a 42.39% decline year-over-year.
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for the quarter ending 2017-09-30 was $116.00K, a 18.31% decline year-over-year.
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for the quarter ending 2017-06-30 was $223.00K, a 25.91% decline year-over-year.
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for fiscal 2017 was $770.00K, a 39.18% decline from fiscal 2016.
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for fiscal 2016 was $1.27M, a 69.87% decline from fiscal 2015.
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for fiscal 2015 was $4.20M, a 20.94% decline from fiscal 2014.
- Ernexa Therapeutics Inc. capital leases, income statement, sales type lease revenue for fiscal 2014 was $5.32M, a 208.29% increase from fiscal 2013.
| Period end | Capital Leases, Income Statement, Sales Type Lease Revenue 3 month | Capital Leases, Income Statement, Sales Type Lease Revenue 6 month | Capital Leases, Income Statement, Sales Type Lease Revenue 9 month | Capital Leases, Income Statement, Sales Type Lease Revenue 12 month |
|---|---|---|---|---|
| 2018-03-31 | $679.00K 10-Q · filed 2018-05-11 | $925.00K derived: sum of 2 quarters · filed 2018-05-11 | $1.04M derived: sum of 3 quarters · filed 2018-05-11 | $1.26M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-12-31 | $246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $362.00K derived: sum of 2 quarters · filed 2018-03-09 | $585.00K derived: sum of 3 quarters · filed 2018-03-09 | $770.00K 10-K · filed 2018-03-09 |
| 2017-09-30 | $116.00K 10-Q · filed 2017-11-08 | $339.00K derived: sum of 2 quarters · filed 2017-11-08 | $524.00K 10-Q · filed 2017-11-08 | $951.00K derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-06-30 | $223.00K 10-Q · filed 2017-08-04 | $408.00K 10-Q · filed 2017-08-04 | $835.00K derived: sum of 3 quarters · filed 2018-05-11 | $977.00K derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-03-31 | $185.00K 10-Q · filed 2018-05-11 | $612.00K derived: sum of 2 quarters · filed 2018-05-11 | $754.00K derived: sum of 3 quarters · filed 2018-05-11 | $1.05M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $569.00K derived: sum of 2 quarters · filed 2018-03-09 | $870.00K derived: sum of 3 quarters · filed 2018-03-09 | $1.27M 10-K · filed 2018-03-09 |
| 2016-09-30 | $142.00K 10-Q · filed 2017-11-08 | $443.00K derived: sum of 2 quarters · filed 2017-11-08 | $839.00K 10-Q · filed 2017-11-08 | $1.97M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $301.00K 10-Q · filed 2017-08-04 | $697.00K 10-Q · filed 2017-08-04 | $1.82M derived: sum of 3 quarters · filed 2017-08-04 | $2.81M derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | $396.00K 10-Q · filed 2017-05-04 | $1.52M derived: sum of 2 quarters · filed 2017-05-04 | $2.51M derived: sum of 3 quarters · filed 2017-05-04 | $3.76M derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $2.11M derived: sum of 2 quarters · filed 2017-03-09 | $3.36M derived: sum of 3 quarters · filed 2017-03-09 | $4.20M 10-K · filed 2017-03-09 |
| 2015-09-30 | $984.00K 10-Q · filed 2016-11-09 | $2.23M derived: sum of 2 quarters · filed 2016-11-09 | $3.08M 10-Q · filed 2016-11-09 | $4.80M derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | $1.25M 10-Q · filed 2016-08-04 | $2.09M 10-Q · filed 2016-08-04 | $3.81M derived: sum of 3 quarters · filed 2016-08-04 | $4.70M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | $840.00K 10-Q · filed 2016-05-09 | $2.56M derived: sum of 2 quarters · filed 2016-05-09 | $3.45M derived: sum of 3 quarters · filed 2016-05-09 | $5.04M derived: sum of 4 quarters · filed 2016-05-09 |
| 2014-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $2.61M derived: sum of 2 quarters · filed 2016-03-15 | $4.20M derived: sum of 3 quarters · filed 2016-03-15 | $5.32M 10-K · filed 2016-03-15 |
| 2014-09-30 | $889.00K 10-Q · filed 2015-11-09 | $2.48M derived: sum of 2 quarters · filed 2015-11-09 | $3.59M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $1.59M 10-Q · filed 2015-08-10 | $2.70M 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $1.11M 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | $1.72M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |